
EPIDEMIOLOGICAL AND CLINICAL PROFILE OF IRAQI PATIENTS WITH B-THALASSEMIA MAJOR

Ebtissam Yasseen Ali¹ Maysaloun Muhammed Abdulla²

1 Mb.Ch.B, M.O.H./Al-Najaf

2 Mb.Ch.B, D.C.M, F.I.C.M.S/CM, Professor, Community & Family Medicine Department/College of Medicine/Al-Nahrain University, P.O.Box: 70044 Kadhimiya
(Corresponding author)

ABSTRACT: *Thalassemia is an autosomal recessive inherited blood disorder due to hemoglobin-production abnormalities. The study aims to identify the Sociodemographic and clinical characteristics of patients with thalassemia. A cross-sectional study was conducted at Thalassemia Center in Al-Najaf province, during the period from April 1st to August 31st 2018. Data were collected through direct interview with patients/parents. A total of 175 transfusion dependent thalassemia major patients were included, the mean age 10.5 years, ranging from 5 m to 34 years. Patients under 10 years of age represented the highest rate with Male: Female ratio 1.2:1. 60% were from rural area with high percentage of parental consanguinity (70%). The majority of patients had high serum ferritin level which was associated with multiple complications such as cardiac and endocrine problems and one third had underwent splenectomy. Development of preventive measures as genetic counseling, prenatal diagnosis, pre-marital screening are the best ways to decrease the incidence of disease, in addition to regular blood transfusion with optimum chelation therapy.*

KEYWORDS: thalassemia, epidemiology, anaemia.

INTRODUCTION

Thalassemia syndromes refers to a spectrum of diseases characterized by reduced or absent of one or more globin chain. Thalassemia was not recognized as clinical entity until 1925 where Cooley and Lee described a syndrome occurring in children of Italian origin and associated with splenomegaly and bone change¹. Mutations in the beta-globin gene cluster occur at high frequencies (>1%) in regions including the Mediterranean, Middle East, northern Africa, India, and almost all of Southeast Asia². Although the prevalence of these mutations is low in the populations of northern Europe and North America, widespread immigration has led to worldwide distribution.^{3, 4, 5}

There is a little data on epidemiology and burden of thalassemia in Iraq. Thalassemia represented 75% of all hemoglobinopathies in Iraq and beta- thalassemia major represent 67% of all type of thalassemia⁶.

A variety of mutations in the gene or its regulatory elements cause defects in the initiation or termination of transcription, abnormal RNA splicing or cleavage, substitutions, and frame shifts. The result is decreased or absent production of beta-globin chains, giving rise to the beta-thalassaemia syndromes. The underlying pathophysiology of beta-thalassaemia syndromes is ineffective erythropoiesis. In beta-thalassaemia major there is a complete or near-complete lack of beta-globin, leading to a transfusion-dependent severe anaemia⁷.

Thalassaemia may be classified into Genotypic classification; Heterozygous beta-thalassaemia (beta-thalassaemia trait) and Homozygous beta-thalassaemia,⁸ and Phenotypic classification; Silent carrier, B Thalassaemia minor, β Thalassaemia intermedia and β Thalassaemia major^{1,9,10, 11}. The severity of the clinical manifestation and laboratory findings in thalassaemia largely depends on the genotype. Thalassaemia major (Cooley's anemia) patients develop a severe, life-threatening anemia during their first year or two of life. To survive childhood, they require chronic transfusion therapy to correct their anemia and suppress their high level of ineffective erythropoiesis. Beta-thalassaemia major and intermedia are genetic conditions associated with significant morbidity and a decreased life expectancy^{12, 13, 14, 15}. All women at risk for being carriers, based on family history or ethnic background, should be antenatal screened by blood counts and haemoglobin analysis, and should be offered antenatal diagnosis and genetic counseling¹⁶.

The average rate of Hb fall in patients is with thalassaemia major is 1g/dl per week. regular blood transfusion usually administered every two to five weeks to maintain the pretransfusion hemoglobin level above 9 – 10.5 g/dl. Doing so can cause a high amount of iron to build up in the body, which can be harmful. Persons who receive significant numbers of blood transfusions need a treatment called chelation therapy to remove excess iron from the body¹¹. Deferoxamine (Desferal) is given 5–6 days a week at a dose of 20–40 mg/kg/day^{11, 12}. Deferasirax (Exjade) is an orally active chelator that is highly selective for iron, Promotes excretion of iron in the feces. The recommended initial dose of Exjade is 20 mg/kg bodyweight once daily¹² and Deferiprone is a new iron chelator used for children >2 year of age. Adverse effects of deferiprone include agranulocytosis, arthropathy which necessitates discontinuation of the therapy. Gastrointestinal intolerance, zinc deficiency and fluctuation of liver enzymes are other side effects¹⁷. Thalassaemia is often accompanied by the destruction of a large number of red blood cells, and the task of removing these cells causes the spleen to enlarge¹³. Severe enlargement of the spleen more than 6cm below the costal margin and the presence of leucopenia or thrombocytopenia may necessitate its removal. splenectomy can have serious consequences, including infection, pulmonary hypertension, and thrombosis. the patient should be fully immunized against encapsulated bacteria before splenectomy and subsequently should be on long term penicillin prophylaxis^{12, 14}. All children who have an HLA-matched sibling should be offered the option of bone marrow transplantation in which substitution normal stem cells for stem cells harboring defective globin genes. It offers the only cure available for B-thalassaemia major, should be considered for patients at an early age (children younger than 15 years of age) or before complications due to iron overload have developed¹⁵. In gene therapy; the bone marrow of patient is harvested and beta globin gene is incorporated into stem cells and reinfused in the body system. This is done by transfer of recombinant DNA into human cells for correction of disease. There are viral and non-viral vectors for gene expression¹⁵

Blood transfusions can result in too much iron, which can damage the heart, liver, and endocrine system. Less. Early recognition and prevention of the endocrine complications, by early and regular chelation therapy, is mandatory for the improvement of the quality of life and psychological outcome of these patients¹⁸. Patients with multi-transfused thalassaemia major may develop severe endocrine complications due to iron overload. The anterior pituitary is particularly sensitive to iron overload which disrupts hormonal secretion resulting in hypogonadism, short stature, acquired hypothyroidism and hypoparathyroidism. Glucose intolerance and diabetes mellitus are also common in thalassaemic patients¹⁹. Monitoring should be performed regularly for the following complications; 1) Iron load, Consistent rising serum ferritin levels or intermittent transfusions given at a volume likely to require chelation²⁰ 2) Cardiovascular by Cardiac MRI annually, 3) Hepatobiliary by Holter monitoring annually, 4) Bilirubin levels and AST/ALT monitoring at each transfusion visit if on deferasirax or if active hepatitis B virus or hepatitis C virus infection; less frequently if on desferrioxamine, 5) Hepatitis B virus and hepatitis C virus serology annually, 6) Renal monitoring for Urea and serum creatinine at each transfusion visit if on desferrioxamine or deferasirax, 7) Endocrine, for Thyroid and parathyroid function annually, 8) monitoring for Bone density, Glucose tolerance, HIV serology, Vision and hearing are done annually, 8) HCG, testicular, and ovarian function monitoring is based on age and clinical indication while Pulmonary function is monitored every 2 years²¹.

Life expectancy of Beta-thalassaemia trait has no difference from normal²². While Beta-thalassaemia intermedia may have significant cosmetic changes in appearance which may interfere with quality of life, Beta-thalassaemia major; If untreated, is usually fatal in the first few years of life, death being the result of heart failure secondary to severe anaemia²³.

The aim of this study is to determine the Sociodemographic characteristics and to assess the clinical aspects of beta- thalassaemic major blood transfusion dependent patients at thalassaemia center in Al-Zahraa hospital at Al-Najaf governorate.

PATIENTS AND METHODS

A cross sectional study was performed at Thalassaemia center in Al-Zahraa Hospital at Al-Najaf province/Iraq, this center contains four wards, it affords services for about one thousand of patient with different types of hemoglobinopathies and all the patients receive different types of health care services such as counselling and management especially blood transfusion. The study was conducted for the period from April 1st to August 31st 2018, three days a week and four hours per day. A convenience sample of B Thalassaemia patients attending Thalassaemia Centre during the study period was selected. Data were collected through direct interview with patients/parents and from patients' records using a pre tested structured questionnaire form which was specially designed for this study. Only thalassaemia major patients with blood transfusion were included.

Data collected were related to; sociodemographic characteristics such as age (in years), gender (male or female), residence (urban or rural) and parental consanguinity, in addition to information about B thalassaemia which consisted of; age at diagnosis and the age at first blood transfusion in years; classified into 4 categories (under 1 year, 1- <2 years, 2- <3 years and 3+ years), Interval of blood transfusion in weeks, type of transfused blood cells (filtered blood cell or non-phenotypically RBC), Chelation history such as; age of first chelation and type of chelating agent

(Deferoxamine, Deferasiraox, or Deferiprone), History or presence of infectious disease due to blood transfusion such as Hepatitis B, Hepatitis C, and HIV.

Serum ferritin level was estimated for all patients in this study which was grouped into 4 categories; 1001-1500 ng/ml, 1501-2500 ng/ml, 2501-5000 ng/ml, and >5000 ng/ml). Other variables included were; History of splenectomy (as a treatment for B thalassemia), vaccination after splenectomy, type of vaccination, type of prophylactic antibiotics, and Complications associated with B thalassemia whether cardiac, endocrine or other complications.

The study protocol was reviewed and approved by scientific committee at Family and Community Medicine Department at Alnahrain college of Medicine. Approval and official permissions were obtained from; the Iraqi Board of Medical Specialties, and Al-Najaf Health Office and Administration of Al-Zahraa Hospital and Thalassemia center.

All participants were given enough information, in a way they can understand, about the potential benefits of being involved in study and that information obtained would be confidential. A verbal consent from each participant/parent was obtained prior to the start of data collection. Data of the studied group were entered and analyzed by using the statistical package for social sciences (SPSS) version 23. Descriptive statistics were presented as frequencies, proportions (%), means and standard deviation (SD). Chi square test was used to estimate the association between two categorical variables. Level of P value < 0.05 was considered as significant. A pilot study was carried out on a sample from thalassemia center consisted of twenty B thalassemic patients selected randomly and interviewed. Those patients were not included in the current study. The purpose of the pilot study was to assess the feasibility of questionnaire and the time required for each interview, and to find out if there would be any difficulty/obstacle to conduct the study, so that possible change or correction to the questionnaire could be made accordingly.

RESULTS

A total of 175 patients with thalassemia major were included in this study. Mean age \pm SD (10.5 years \pm 5.8 years) and the range from 5 months to 34 years, 94(54%) were males and 81(46%) were females with a ratio 1.2: 1 (figure 1).




Figure 1: Distribution of thalassemia major patients according to sex (N= 175).

More than half (55%) aged 1 to 10 years. The highest rate (60%) of patients were from rural areas. Parental consanguinity, of different degrees, was positive in 70% (110) of cases. 81 (46.2%) patients were diagnosed as thalassemia in their first year of life and age at diagnosis of 36 (20.5%) patients was after 3 years of age (Table-1).

Table-1: Distribution of patients with thalassemia major according to Sociodemographic characteristics.

Sociodemographic characteristics	Frequency (%)
Mean age \pmSD	10.5 years \pm 5.8
Range	(5 months - 34 years)
Age group(years)	
<1years	12(6.85%)
1-5years	44(25%)
> 5-10years	54(30.8%)
>10 years	65(37%)
Age of diagnosis	
<1 year	81(46.2%)
1 - 2 years	29(16.5%)
2- 3years	29(16.5%)
3+years	36(20.5%)
Residence	
Urban	70(40.2%)
Rural	105(60%)
Consanguinity	
Yes	110(70%)
No	65(30%)
total	175

Majority of patients (72.6%) had blood transfusion at 3-4 weeks interval, while on emergency transfusion was found in only 4% of the study sample. Type of transfused blood cells was filtered blood cells in about 79.4% (139) of patients while the rest 36 (20.5%) received non phenotypically red blood cells. Transfusion-transmitted infection was found among 7 (4 %) patients; Hepatitis B (2.2%) and Hepatitis C (1.7 %) viral infections, while no HIV infection was detected (Table 2).

Table-2: Distribution of thalassemic major patients according to blood transfusion characteristics.

Blood transfusion characteristics	Frequency(%)
Transfusions Interval	
3-4 weeks	127(72.6%)
5-6 weeks	27 (15.4%)
7-8 weeks	14 8%)
On emergency	7 (4%)
Type of transfused blood cells	
Filtered blood cells	139 (79.4%)
Non-phenotypically RBC	36 (20.5%)
Transfusion transmitted infection	
Hep B	4 (2.2%)
Hep C	3 (1.7%)
HIV	0(0.0%)

Chelation therapy was administered to 156 (89%) patients, the age of first chelation in 39.7% of them was before 3 years of age while the rest (approximately 60%) had it at the age of 3 years and above. Deferoxamine was the most commonly used iron chelator 92(52.6%), Table-3.

Table-3: Distribution of thalassemic major patients according to chelation therapy and ferritin level.

Variables	Frequency (%)
Age of first chelation (N=156)	
<3 years	62 (39.7%)
3+	94 (60.3%)
Type of chelation therapy(N=156)	
Deferoxamine	92(52.6%)
Deferasirax	43(24.6)
Deferiprone	21(12.8%)
Serum ferritin level (N=175)	
<1500	41 (23.4%)
1500-2500	64 (36.5%)
2501-5000	52(29.7%)
>5000	18 (10.4%)

Serum ferritin level was done for all patients participated in this study and the results were as follow; 41 patients(23.4%) had serum ferritin level between 1001-1500ng/ml, a moderate iron

overload between 1501-2500ng/ml was found in 64 patients (36.5%), 52 patients (29,7%) between 2500-5000ng/ml ,while those with a level above 5000 ng/ml was 18 patients (10%) only (Table-3). Splenectomy was done for 63 (36%) patients and the mean age of splenectomy was 8.3 years \pm 2.5.(figure 2).




Figure-2: Distribution of thalassemic patients according to splenectomy

Thalassemic patients at thalassemia center were vaccinated against multiple microorganisms such as; streptococcus pneumonia (87.4%), H. Influenza type b (77.2%) and Neisseria meningitis (80.6%), (Table-4). Prophylactic antibiotics which were administered to splenectomized patients either Benzathin penicillin (55.8%) or oral penicillin (40%), (Table-4).

Table-4 distribution of thalassemia major patients according to vaccination and prophylactic antibiotics

Variable	Frequency (%)
Vaccination (N= 63)	
Type of vaccination	
Streptococcus pneumonia	55 (87.4%)
H influenza type b	48(77.2%)
Neisseria meningitis	51(80.6%)
Prophylactic antibiotics (N=63)	
Types of antibiotics	
Benzathin-penicillin	44 (69.84%)
Oral penicillin	19 (30.16%)

The rates of complications among transfusion dependent patients in the current study were as follow; 16% (28) of all patients had cardiac problems (arrhythmia 3 (10.7 %), heart failure 18 (64.2 %) and pulmonary hypertension 7 (25 %) patients), figure-3, endocrine disorders such as delayed puberty in 56 (32%) patients, Growth retardation in 19 (10.8%) patients, Thyroid disorders in 5.1% (9 cases) of patients, and Diabetes mellitus was seen in 6 (3.4%) cases (table 5). The association of different complications with; blood transfusion intervals and serum ferritin level among patients with thalassemia, are shown in tables 6 and 7 respectively.




Figure 3:Types of cardiac disorders among Patients with thalassemia major (N=175).

Table-5: Distribution of patients with thalassemia major according to endocrine complication .

Endocrine complication	Frequency (175)(%)
Delayed puberty	56 (32%)
Growth retardation	19 (10.8%)
Thyroid disorder	9 (5.1%)
Diabetes mellitus	6 (3.4%)

Table-6: Distribution of patients with thalassemia major according to complications by transfusion interval

complication	Blood transfusion interval					P value
	3-4 week	5-6 week	7-8 week	On emergency	Total	
Cardiac						
Yes	11(6.3%)	9(5.1%)	5(2.9%)	3(1.7%)	28(16%)	0.001
no	116(66.3%)	18(10.3%)	9(5.1%)	4(2.3%)	147(84%)	
Delay puberty						
Yes	25(14.3%)	17(9.7%)	11(6.3%)	3(1.7%)	56(32%)	0.001
No	102(58.3%)	10(5.7%)	3(1.7%)	4(1.3%)	119(68%)	
Growth Retardation						
Yes	9(5.1%)	5(2.9%)	4(2.3%)	1(0.6%)	19(10.8%)	0.043
No	118(67.4%)	22(12.6%)	10(5.7%)	6(3.4%)	156(89.1%)	
Thyroid dysfunction						
Yes	6(3.4%)	2(1.1%)	1(0.6%)	0(0.0%)	9(5.1%)	0.829
No	121(69.1)	25(14.3%)	13(7.4%)	7(4%)	166(94.8%)	
Diabetes						
Yes	3(1.7%)	1(0.6%)	1(0.6%)	1(0.6%)	6(3.4%)	0.318
No	124(70.8%)	26(14.8%)	13(7.4%)	6(3.4%)	169(96%)	

Table 7: Distribution of patients with thalassemia major according to endocrine complications by serum ferritin level.

Endocrinopathy	Total number	Ferritin level <1500	1500-2500	2501-5000	>5000	P value
Delayed puberty						
Yes	56 (32%)	7 (4%)	9 (5.1%)	23 (13.1%)	17 (9.7%)	0.0001
No	119 (68%)	34 (19.4%)	55 (31.4%)	29 (16.6%)	1 (0.6%)	
Growth retardation						
Yes	19 (10.9%)	5 (2.9%)	4 (2.3%)	6 (3.4%)	4 (2.3%)	0.4288
No	156 (89.1%)	36 (20.8%)	60 (34.3%)	46 (26.3%)	14 (8%)	
Thyroid disorders						
Yes	9 (5.14%)	2 (1.1%)	2 (1.1%)	3 (1.7%)	2 (1.1%)	0.5942
No	166 (94.8%)	39 (22.3%)	62 (35.4%)	49 (28%)	16 (9.1%)	
Diabetics						
Yes	6 (3.4%)	2 (1.1%)	1 (0.6%)	2 (1.1%)	1 (0.6%)	0.5680
No	169 (96.6%)	39 (22.3%)	63 (36%)	50 (28.6%)	17 (9.7%)	

DISCUSSION

Thalassemia major happen when a child inherits two mutated genes from father and mother. Children born with this disease usually develop severe anaemia during their first year of life. They lack the ability to produce adult Hb, consequently this will lead to growth retardation, impaired physical activities, bone changes and enlargement of liver and spleen. The only treatment to correct anaemia is regular blood transfusion and chelation therapy¹.

A slight male predominance was found in this study with a male to female ratio of 1.2:1 which is in agreement with similar studies carried out by Zamani et al in Iran and in Tunisia which revealed percentage of males 54.9% and 55.4% respectively^{24, 25}. A similar sex ratio was found in a study conducted in Bangladesh in 2017, which reported a male to female ratio of 1.14:1²⁶. The mean age

among thalassemic patients in the current study was 10.5 years and range 5 month- 34 years, similar to that reported by Bejaoui and Gurrat (10.7 years) in Tunisia²⁵

In contrast to our study, a comparatively higher mean age of thalassemic patients was shown in Iranian cohort in 2013 (15.2 years) and United Arab Emirates study (15.4 years)^{24, 27}, and a much higher in North America (20 years)^{28, 29}. This could be explained by late detection of the disease in Iraq because of low level of community awareness of the disease and fewer available facilities to seek medical advice. On the other hand, lower mean age was reported in India in 2016³⁰. Half of thalassemic patients in this study were first diagnosed during their first year of life, similar to a study carried out in India³⁰. Modell and Berdoukas³¹ reported 60% of their patients had presented clinically in the first year of life.

The prevalence of thalassemia major is high in countries where there are relative marriages. Geographic distribution in this research found that majority of thalassemia major patients are from rural areas where relative family marriages commonly occur³². Our result is in agreement with a study done in Iran²⁴, but differs from that shown in the Lebanese study in which thalassemia was homogeneously distributed all over the country³³.

Positive parental consanguinity was found in 70% of all studied patients, this may be explained by the fact that thalassemia is transmitted as an autosomal recessive type. A comparably high consanguinity rate was estimated in the Iranian study²⁴ and a study in Tunisia²⁵. One of the reasons for high rate of parental consanguinity among thalassemic patients could be lack of knowledge and awareness about the risk of thalassemia following familial marriage²⁶.

Blood transfusion and chelation therapy remain the cornerstone of treatment of thalassemia major³⁴. There are several risks due to chronic blood transfusion like; infection, iron overload because of repeated blood exposure³⁵. A High percentage of patients receiving chelation therapy 89% (156) was reported in current study, similar to a study done in Tunisia²⁵. A comparably lower percentage 40% was reported in Bangladesh in 2017²⁶. The optimal time for initiating iron chelation therapy in patient with thalassemia remains uncertain, in theory it should start as early as possible to prevent complications. Federation recommended that chelation initiated when serum ferritin levels reach approximately 1000ng/ml, which usually occurs after the first 10-20 transfusions or around 2-3 years old^{36, 37}, in this study the rate was 39.7% under 3 years. The delay age of initiation of chelating therapy is related to literacy (ignorance) hence the delay in seeking medical advice until complication appearance^{36, 38}.

Iron over load associated endocrine complication were reported in 60% of chronically transfused thalassemia major patients with a dysfunction of at least one gland^{39, 40}, these include delayed puberty, growth retardation thyroid disorder and diabetes mellitus. Delayed puberty is the most common complication in this study, a finding consistent with Italian cohort in which hypogonadism was reported in 50% of patients⁴¹ while prevalence of growth retardation (26.7%) was higher than that reported in Italy (5%)⁴², hypothyroidism, diabetes mellitus and hypo parathyroidism were estimated particularly among patients in their second decade of life. No significant association was identified between serum ferritin level and diabetes mellitus among thalassemia patients in the current study. Splenectomy is beneficial in treating thalassemia major,

it decreases patients transfusion requirements and increases the mean level of hemoglobin¹⁸. 36% of our patients underwent splenectomy and this may indicate that previous transfusion therapy had been inadequate in at least some of them. There is a risk of invasive bacterial infections supported by data collected by Bisharat et al.¹⁹. Thus prevention and treatment of bacterial infection are life saving measure, splenectomized cases should receive routine vaccination including both live attenuated and killed vaccine but they should also be vaccinated against *Streptococcus pneumoniae*, *H. influenzae* type b, and *Neisseria meningitidis*. In addition to administration of prophylactic antibiotics to complete protection against infection with encapsulated bacteria¹⁹. The goal of transfusion is to shut off erythropoiesis as much as possible. Transfusions should be scheduled in advance and maintained at a fixed schedule. This enables patients and families to establish routines and will improve quality of life.

The recommended treatment for thalassaemia major involves lifelong regular blood transfusions, usually administered every two to five weeks, to maintain the pre-transfusion haemoglobin level above 9-10.5 g/dl. This transfusion regimen promotes normal growth, allows normal physical activities, adequately suppresses bone marrow activity in most patients, and minimizes transfusional iron accumulation.

This study showed a relation between blood transfusion intervals and cardiac complications. Iron overload was found to be associated with endocrinopathy such as delayed puberty and growth retardation which were frequently reported complications among chronically transfused patients and have relation with infrequent blood transfusion. Blood transfusion intervals in patients with thalassaemia major who have some endocrine complications (diabetic mellitus and thyroid dysfunction) were not significantly different from those without those complications. Although shorter intervals between blood transfusions may reduce overall blood requirements, the choice of interval must take into account other factors such as the patient's school or work schedule and other lifestyle issues.

CONCLUSIONS

The highest rates of B thalassaemic patients were; under 10 years, males, from rural areas with high percentage of parental consanguinity. Most blood transfusion dependent patients were regularly transfused, chelation therapy was administered to majority of patients with deferoxamine as the most commonly used iron chelator. The majority of patients had high serum ferritin level which was associated with multiple complications such as cardiac and endocrine problems and one third were underwent splenectomy. Most of the patient in current study received vaccination and prophylactic antibiotics.

Development of preventive measures as genetic counseling, prenatal diagnosis, pre-marital screening are the best ways to decrease the incidence of disease, in addition to regular blood transfusion with optimum chelation therapy including optimum age of starting of chelation dose and frequency per week. Health education about thalassaemia by periodic sessions for targeted groups should be done as a strategy to increase the awareness about the mortality and morbidity specifically of transfusion dependent thalassaemia major patients who should do regular routine

investigations and monitoring of iron status by serum ferritin level to prevent complications and decrease the burden of the disease.

References

- 1- Nancy F .The Beta-thalassemia.The new England Journal of Medecine,1999;341(2) :99-109.
- 2- Weatherall DJ. The thalassemys. In: Stamatoyannopoulos G, et al., eds. The molecular basis of blood diseases. Philadelphia, PA: WB Saunders Company; 1994:157-205.
- 3- Weatherall DJ, Clegg JB. Inherited haemoglobin disorders: an increasing global health problem. Bull World Health Organ. 2001; 79:704-712.
- 4- Angastiniotis M, Modell B. Global epidemiology of hemoglobin disorders. Ann N Y Acad Sci. 1998; 850:251-269
- 5- Colah R, Gorakshakar A, Nadkarni A. Global burden, distribution and prevention of beta-thalassemys and hemoglobin E disorders. Expert Rev Hematol. 2010; 3:103-117.
- 6- Kamel A Kadhim,Kadhim H Baldawi and Faris Lami. Prevalence, Incidence, Trend and Complication of Thalassemy in Iraq. Hemoglobin. 2017 May;41(3):164 168.
- 7- Thein SL. The Molecular Basis of β -Thalassemy. Cold Spring Harb Perspect Med. 2013 May; 3(5).
- 8- Galanello R. Recent advances in the molecular understanding of non-transfusion-dependent thalassemy. Blood Rev. 2012;26(suppl 1): S7-S11
- 9- Trehan A, Sharma N, Das R, Bansal D, Marwaha RK. Clinicoinvestigational and demographic profile of children with thalassemy major. Indian J Hematol Blood Transfus 2015; 31:121–126.
- 10- Kumar S, Singh D, Garg A. An epidemiological study on the clinico-hematological profile of pediatric patients with congenital hemolytic anemia. Int J Contemp Pediatr 2017; 4:374–377.
- 11- Koren A, Profeta L, Zalman L, Palmor H, Levin C, Zamir RB et al. Prevention of beta thalassemy in Northern Israel: a cost-benefit analysis. Mediterr J Hematol Infect Dis 2014; 6:e2014012.
- 12- Berdoukas V, Farmaki K, Wood JC, et al. Iron chelation in thalassemy: time to reconsider our comfort zones. Expert Rev Hematol. 2011; 4:17-26.
- 13- Farmaki K, Tzoumari I, Pappa C, et al. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol. 2010
- 14- Cappellini MD, Cohen A, Porter J, et al; Thalassaemia International Federation. Guidelines for the management of transfusion dependent thalassaemia (TDT). 3rd ed. 2014. <http://www.thalassaemia.org.cy/> (last accessed 8 July 2017).
- 15- Piomelli S. The management of patients with Cooley's anemia: transfusions and splenectomy. Semin Hematol. 1995; 32:262-268.
- 16- Jensen PD. Evaluation of iron overload. Br J Haematol. 2004; 124:697-71.
- 17- Wood JC. Magnetic resonance imaging measurement of iron overload. Curr Opin Hematol. 2007; 14:183-190.
- 18- Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemy. Blood. 1997; 89:739-761. [Erratum in: Blood. 1997; 89:2621.]

- 19- Gandon Y, Olivie D, Guyader D, et al. Non-invasive assessment of hepatic iron stores by MRI. *Lancet*. 2004 Jan 31;363(9406):357-62.
- 20- Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. *Eur Heart J*. 2001; 22:2171-2179 .
- 21- Maggio A, Filosa A, Vitrano A, et al. Iron chelation therapy in thalassemia major: a systematic review with meta-analyses of 1520 patients included on randomized clinical trials. *Blood Cells Mol Dis*. 2011; 47:166-175.
- 22- Angelucci E, Brittenham GM, McLaren CE, et al. Hepatic iron concentration and total body iron stores in thalassemia major. *N Engl J Med*. 2000; 343:327-331
- 23- Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Survival and complications in thalassemia. *Ann N Y Acad Sci*. 2005; 1054:40-47.
- 24- Zamani R, Khazaei S, Rezaeian S. Survival analysis and its associated factors of beta thalassemia major in Hamadan Province. *Iran J Med Sci* 2015; 40:233–239.
- 25- Bejaoui M, Guirat N. Beta thalassemia major in a developing country: epidemiological, clinical and evolutionary aspects. *Mediterr J Hematol Infect Dis* 2013; 5:e2013002.
- 26- Hossain MS, Raheem E, Sultana TA, Ferdous S, Nahar N, Islam S et al. Thalassemias in South Asia: clinical lessons learnt from Bangladesh. *Orphanet J 3Rare Dis* 2017; 12:93.
- 27- Hajipour M, Rezaeian S, Abdollahi M, Semati A, Shafiee M, Sharafi M et al. Combined chelation therapy and survival of beta-thalassemia major: a retrospective cohort study. *Ann Public Health Res* 2015; 2:1020.
- 28- Li CK, Luk SW, Ling SC, Chik KW, Yuen HL, Li CK et al. Morbidity and mortality patterns of thalassemia major patient in pediatric department of three regional hospital: retrospective study. *Hong Kong Med J* 2002; 8:255–260.
- 29- Kremastinos DT, Farmakis D. Iron overload cardiomyopathy in clinical practice. *Circulation* 2011; 124:2253–2263.
- 30- Choudhari S, Behera MK. Chelation status & clinical profile of thalassaemic children attending paediatric clinics. *Indian J Appl Res* 2016; 6:276–278.
- 31- Arandi N, Haghpanah S, Safaei S, Zahedi Z, Ashrafi A, Eatemadfar P et al. Combination therapy – deferasirox and deferoxamine – in thalassemia major patients in emerging countries with limited resources. *Transfus Med* 2015; 25:8–12.
- 32- Ghosh S., Bandyopadhyay SK, Bandyopadhyay R, Maisnam I, Ghosh MK. A study on endocrine dysfunction in thalassaemia. *J Indian Med Assoc* 2008; 106:655–659.
- 33- Inati A, Zeineh N, Isma'eel H, Koussa S, Gharzuddine W, Taher A. B-Thalassemia: the Lebanese experience. *Clin Lab Haem* 2006; 28:217–227.
- 34- Telfer P, Coen PG, Christou S, Hadjigavriel M, Kolnakou A, Pangalou EK, et al. Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1908–2004. *Haematologica*. 2006; 91:1187–1192.
- 35- Wonke B, Hoffbrand AV, Brown D, Dusheiko G. Antibody to hepatitis C virus in multiply transfused patients with thalassaemia major. *J Clin Pathol*. 1990; 43:638–640.
- 36- Kontoghiorghe CN, Andreou N, Constantinou K, Kontoghiorghe GJ. World health dilemmas: orphan and rare diseases, orphan drugs and orphan patients. *World J Methodol* 2014; 4:163–188.

- 37- Poggiali E, Cassinerio E, Zanaboni L, Cappellini MD. An update on iron chelation therapy. *Blood Transfus* 2012; 10:411–422.
- 38- Cao A, Galanello R, Rosatelli MC, Argiolu F, DeVirgiliis S. Clinical experience of management of thalassemia: the Sardinian experience. *Semin Hematol*. 1996; 33:66–75.
- 39- Aydinok Y, Darcan S, Polat A, Kavakli K, Nigli G, Coker M, et al. J Endocrine complications in patients with beta-thalassemia major. *Trop Pediatr*. 2002; 48:50.
- 40- Choudhari S, Behera MK. Chelation status & clinical profile of thalassemic children attending paediatric clinics. *Indian J Appl Res* 2016; 6:276–278.
- 41- Elalfy MS, Adly AM, Wali Y, Tony S, Samir A, Elhenawy YI. Efficacy and safety of a novel combination of two oral chelators deferasirox/ deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients. *Eur J Haematol* 2015; 95:411–420.
- 42- De Sanctis V, Eleftheriou A, Malaventura C. Prevalence of endocrine complications and short stature in patients with thalassaemia major: a multicenter study by the Thalassaemia International Federation (TIF) *Pediatr Endocrinol Rev*. 2004;2:249–255.